NOVANTA INC.
At today's price, NOVANTA INC. (NOVT) is priced for today's economics sustained for ~16.1 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
• Novanta builds precision photonics, motion-control, and medical components that get designed into other companies' machines, surgical robots, lasers, automation systems, and medical devices, so its revenue compounds as those platforms scale. • The defining risk is the price: at roughly 56 times earnings the stock trades above what every valuation lens supports, so the buyer is paying for many years of durable high-margin growth to come true rather than for the business as it stands. • The next
Is NOVT overvalued? See what's priced in →
318 institutional managers reported holding NOVT in 13F filings for the quarter ended 2026-03-31. 40 opened new positions that quarter. Held by BlackRock, Vanguard Group, T. Rowe Price, among others. On the short side, 4.7M shares were sold short as of the 2026-06-15 count, about 11% of shares outstanding (8.7 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
NOVT's share count grew 14.3% over the past five years even with $67.92M spent on repurchases. It pays no dividend. Cash returned over the past three years: $57.92M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at NOVT over the trailing three years. Absence is a fact about the company, not a signal. 15 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
NOVT's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-09 | -11.3% | -3.4% |
| 2023-11-08 | -11.0% | +29.0% |
| 2024-02-29 | +9.9% | -7.7% |
| 2024-05-08 | -1.6% | +0.4% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
NOVT's latest 8-K filings: 2026-06-09 (items 1.01, 3.02, 8.01, 9.01); 2026-06-09 (items 1.01, 7.01, 9.01); 2026-05-29 (items 5.07); 2026-05-15 (items 1.01, 2.03, 9.01); 2026-05-11 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.